MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturities
of short-term...
$486,030K
Proceeds from stock
option exercises
$12,138K
Proceeds from espp
$1,538K
Net cash provided by
(used in) investing...
$290,036K
Net cash provided by
financing activities
$13,676K
Canceled cashflow
$195,994K
Net (decrease)
increase in cash, cash...
-$19,268K
Canceled cashflow
$303,712K
Stock-based compensation
$47,503K
Accrued expenses and
other current...
$42,167K
Accounts payable
$4,954K
Provision for credit
losses
$3,667K
Non-cash operating lease
expense
$946K
Amortization of debt issuance
costs
$228K
Inventory reserves
$163K
Depreciation
$6K
Purchases of short and
long-term investments
$195,807K
Purchases of property and
equipment
$187K
Net cash used in
operating activities
-$322,980K
Canceled cashflow
$99,634K
Net loss
-$285,422K
Collaboration (payable)
receivable, net
-$42,976K
Inventory
$32,091K
Accounts receivable
$30,394K
Prepaid expenses and
other current assets
$14,542K
Accretion of investments
$10,753K
Other receivable
$6,436K
Back
Back
Cash Flow
source: myfinsight.com
Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (SNDX)